Description

Simple

Clinical

Overview

Reboxetine is an antidepressant drug used in the treatment of clinical depression, panic disorder and ADD/ADHD. Its mesylate (i.e. methanesulfonate) salt is sold under tradenames including Edronax, Norebox, Prolift, Solvex, Davedax or Vestra. Reboxetine has two chiral centers, but it only exists as two enantiomers, (R,R)-(-)- and (S,S)-(+)-reboxetine.

Pharmacology

Indication

For the treatment of clinical depression.

Pharmacodynamic

Reboxetine is a selective noradrenaline reuptake inhibitor (NaRI), the first drug of new antidepressant class. Reboxetine is an a-ariloxybenzyl derivative of morpholine. Reboxetine is primarily used to treat depression but has also been found useful in the treatment of narcolepsy and panic disorders... Read more

Mechanism of action

Reboxetine is a selective inhibitor of noradrenaline reuptake. It inhibits noradrenaline reuptake in vitro to a similar extent to the tricyclic antidepressant desmethylimipramine. Reboxetine does not affect dopamine or serotonin reuptake and it has low in vivo and in vitro affin... Read more

Absorption

Reboxetine is rapidly and extensively absorbed following oral administration.

Protein binding

98%

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

12.5 hours

Route of elimination

Information currently not available.

Toxicity

Reports of seizures (rare) have been reported

Adverse Effects

Contraindications

  • Regions: US
  • Patient Conditions:
      • Name: Narrow angle glaucoma
      • Drugbank Id: DBCOND0104923
  • Regions: US
  • With Categories:
      • Name: Monoamine Oxidase Inhibitors
      • Drugbank Id: DBCAT001004
      • Mesh Id: D008996

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Reboxetine
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
(R)-warfarin
The risk or severity of adverse effects can be increased when Reboxetine is combined with (R)-warfarin.
(S)-Warfarin
The risk or severity of adverse effects can be increased when Reboxetine is combined with (S)-Warfarin.
2,5-Dimethoxy-4-ethylthioamphetamine
The risk or severity of adverse effects can be increased when Reboxetine is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
4-Bromo-2,5-dimethoxyamphetamine
The risk or severity of adverse effects can be increased when Reboxetine is combined with 4-Bromo-2,5-dimethoxyamphetamine.
4-hydroxycoumarin
The risk or severity of adverse effects can be increased when Reboxetine is combined with 4-hydroxycoumarin.
4-Methoxyamphetamine
The risk or severity of adverse effects can be increased when Reboxetine is combined with 4-Methoxyamphetamine.
5-methoxy-N,N-dimethyltryptamine
The risk or severity of adverse effects can be increased when Reboxetine is combined with 5-methoxy-N,N-dimethyltryptamine.
7-Nitroindazole
The risk or severity of adverse effects can be increased when Reboxetine is combined with 7-Nitroindazole.
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline
The risk or severity of adverse effects can be increased when Reboxetine is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.
Acebutolol
The metabolism of Acebutolol can be decreased when combined with Reboxetine.
Acenocoumarol
The risk or severity of adverse effects can be increased when Reboxetine is combined with Acenocoumarol.
Acepromazine
The risk or severity of adverse effects can be increased when Reboxetine is combined with Acepromazine.
Aceprometazine
The risk or severity of adverse effects can be increased when Reboxetine is combined with Aceprometazine.
Acetaminophen
The metabolism of Acetaminophen can be decreased when combined with Reboxetine.
Acetazolamide
The risk or severity of adverse effects can be increased when Reboxetine is combined with Acetazolamide.
Acetophenazine
The risk or severity of adverse effects can be increased when Reboxetine is combined with Acetophenazine.
Acetylglycinamide chloral hydrate
The risk or severity of adverse effects can be increased when Reboxetine is combined with Acetylglycinamide chloral hydrate.
Aclidinium
Reboxetine may increase the central nervous system depressant (CNS depressant) activities of Aclidinium.
Adinazolam
The risk or severity of adverse effects can be increased when Reboxetine is combined with Adinazolam.
Adipiplon
The risk or severity of adverse effects can be increased when Reboxetine is combined with Adipiplon.
4 References
  1. 1 . Fleishaker JC: Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression. Clin Pharmacokinet. 2000 Dec;39(6):413-27.PubMed: 11192474
  2. 2 . Edwards DM, Pellizzoni C, Breuel HP, Berardi A, Castelli MG, Frigerio E, Poggesi I, Rocchetti M, Dubini A, Strolin Benedetti M: Pharmacokinetics of reboxetine in healthy volunteers. Single oral doses, linearity and plasma protein binding. Biopharm Drug Dispos. 1995 Aug;16(6):443-60.PubMed: 7579027
  3. 3 . Wienkers LC, Allievi C, Hauer MJ, Wynalda MA: Cytochrome P-450-mediated metabolism of the individual enantiomers of the antidepressant agent reboxetine in human liver microsomes. Drug Metab Dispos. 1999 Nov;27(11):1334-40.PubMed: 10534319
  4. 4 . Kasper S, el Giamal N, Hilger E: Reboxetine: the first selective noradrenaline re-uptake inhibitor. Expert Opin Pharmacother. 2000 May;1(4):771-82.PubMed: 11249515